[Comment] Antibody–drug conjugates for bladder sparing: lessons from SURE-02 trial

Historically, perioperative cisplatin based neoadjuvant therapy has remained the gold standard for muscle-invasive bladder cancer. In the past 5 years, several practice changing trials have enabled the incorporation of immune checkpoint inhibitors in the perioperative setting for muscle-invasive bladder cancer. The phase 3 NIAGARA study led to the approval of durvalumab in combination with gemcitabine or cisplatin followed by adjuvant…